TRVN:OTCMKTS
Trevena Inc
$0.012
0.00%
(0.00) 1D
Oct 6, 10:01:51 AM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TRVN...
Mkt. cap
10.37K
Avg. vol.
182.00
Volume
2.00
52-wk high
$1.50
52-wk low
$0.00
Beta
1.07
Shares outstanding
864.00K
No. of employees
23
Mkt. cap
10.37K
Avg. vol.
182.00
Volume
2.00
52-wk high
$1.50
52-wk low
$0.00
Beta
1.07
Shares outstanding
864.00K
No. of employees
23
News stories
From web sources and news partners
JournalArta
·
15 minutes ago
Nasdaq rises tech shares as software: What to Know
ChartMill
·
1 day ago
Get insights into the top movers in the S&P500 index of Friday's pre-market session.
Proactive financial news
·
23 hours ago
Frank Talk: Gold miners beat every S&P 500 sector in Q3 despite September selloff
MarketWatch
·
1 hour ago
S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index
Profile
Trevena, Inc. is a clinical stage biopharmaceutical company, headquartered in Chesterbrook, Pennsylvania, USA, and is involved in the discovery and development of G-protein coupled receptors biased ligands. Trevena was founded in 2007 with technology licensed from Duke University, which originated in the labs of company founders Robert Lefkowitz winner of the 2012 Nobel Prize in Chemistry and Howard Rockman. Trevena's approach to drug discovery is based on utilizing ligand bias, or functional selectivity, at GPCR targets to produce drugs with improved efficacy and reduced side effect profiles. Trevena was named one of the top 15 US startups of 2008 by Business Week.
Trevena's expertise lies in engineering "biased ligands" that activate only the beneficial signaling pathways downstream of a GPCR to unlock new biology and avoid drug adverse effects. Trevena's pipeline currently includes a clinical stage mu-opioid biased ligand for post-operative pain, and discovery-stage programs for chronic pain, migraine, and Parkinson's disease. Wikipedia
About Trevena Inc
CEO-
Employees23
Founded2007
HeadquartersAtlanta, Georgia, United States
SectorBiotechnology
Websitetrevena.com